Anthony James Langone M.D.

Department: Medicine

Biography

Dr. Anthony Langone received his medical degree from the State University of New York, School of Medicine and Biological Sciences, Buffalo NY and was a resident of Internal Medicine at Baylor College of Medicine in Houston TX. He completed two fellowships in Nephrology and Transplant Nephrology at Vanderbilt University School of Medicine. He is currently the Medial Director of the Nashville Veteran Affairs Hospital Renal Transplant Program, and Medical Director of the Medical Specialties Clinic at Vanderbilt University. He is an Associate Professor of Medicine in the Division of Nephrology, Department of Medicine, Vanderbilt School of Medicine.

Dr. Langone has been developing his research endeavors in clinical research relating to renal transplantation. In this regard, he has been the PI or co-PI of 25 pharmaceutical-related grants and he was the site PI of 2 multicenter NIH-sponsored trials. He manages a very active clinical service in renal transplantation and general nephrology in both the inpatient and outpatient settings.

Featured Publications

1. Mammalian target of rapamycin inhibitors in organ transplantation: an unkept promise.

Langone AJ, Helderman JH (2012) Chest 142(3): 734-737

Citation ⋅ 22948577 (PubMed)

2. Does reduction in mycophenolic acid dose compromise efficacy regardless of tacrolimus exposure level? An analysis of prospective data from the Mycophenolic Renal Transplant (MORE) Registry.

Langone A, Doria C, Greenstein S, Narayanan M, Ueda K, Sankari B, Pankewycz O, Shihab F, Chan L (2013) Clin Transplant 27(1): 15-24

Citation ⋅ 22861144 (PubMed) PMC3593178 (PubMed Central)

3. Enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients experiencing gastrointestinal intolerance: a multicenter, double-blind, randomized study.

Langone AJ, Chan L, Bolin P, Cooper M (2011) Transplantation 91(4): 470-8

Citation ⋅ 21245794 (PubMed)

See all publications

Publications

1. Mammalian target of rapamycin inhibitors in organ transplantation: an unkept promise.

Langone AJ, Helderman JH (2012) Chest 142(3): 734-737

Citation ⋅ 22948577 (PubMed)

2. Does reduction in mycophenolic acid dose compromise efficacy regardless of tacrolimus exposure level? An analysis of prospective data from the Mycophenolic Renal Transplant (MORE) Registry.

Langone A, Doria C, Greenstein S, Narayanan M, Ueda K, Sankari B, Pankewycz O, Shihab F, Chan L (2013) Clin Transplant 27(1): 15-24

Citation ⋅ 22861144 (PubMed) PMC3593178 (PubMed Central)

3. Enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients experiencing gastrointestinal intolerance: a multicenter, double-blind, randomized study.

Langone AJ, Chan L, Bolin P, Cooper M (2011) Transplantation 91(4): 470-8

Citation ⋅ 21245794 (PubMed)

4. Renal donation after cardiac death.

Shah N, Langone A (2010) J Am Soc Nephrol 21(6): 888-90

Citation ⋅ 20488957 (PubMed)

5. mTOR inhibitor-associated dermatologic and mucosal problems.

Campistol JM, de Fijter JW, Flechner SM, Langone A, Morelon E, Stockfleth E (2010) Clin Transplant 24(2): 149-56

Citation ⋅ 20236129 (PubMed)

6. Recurrent pauci-immune necrotizing crescentic glomerulonephritis in a kidney transplant patient.

Schaefer HM, Langone A, Helderman JH, Fogo AB (2010) Am J Kidney Dis 55(3): 604-8

Citation ⋅ 19782451 (PubMed)

7. Improvement in 3-month patient-reported gastrointestinal symptoms after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients.

Bolin P, Tanriover B, Zibari GB, Lynn ML, Pirsch JD, Chan L, Cooper M, Langone AJ, Tomlanovich SJ (2007) Transplantation 84(11): 1443-51

Citation ⋅ 18091520 (PubMed)

8. Ezetimibe reduces low-density lipoprotein cholesterol (LDL-C) in renal transplant patients resistant to HMG-CoA reductase inhibitors.

Chuang P, Langone AJ (2007) Am J Ther 14(5): 438-41

Citation ⋅ 17890931 (PubMed)

9. Ezetimibe in renal transplant patients with hyperlipidemia resistant to HMG-CoA reductase inhibitors.

Langone AJ, Chuang P (2006) Transplantation 81(5): 804-7

Citation ⋅ 16534487 (PubMed)

10. Polyclonal antibody-induced serum sickness in renal transplant recipients: treatment with therapeutic plasma exchange.

Tanriover B, Chuang P, Fishbach B, Helderman JH, Kizilisik T, Nylander W, Shaffer D, Langone AJ (2005) Transplantation 80(2): 279-81

Citation ⋅ 16041276 (PubMed)

11. The management of the failed renal allograft: an enigma with potential consequences.

Langone AJ, Chuang P (2005) Semin Dial 18(3): 185-7

Citation ⋅ 15934959 (PubMed)

12. Effect of renal transplantation on biomarkers of inflammation and oxidative stress in end-stage renal disease patients.

Simmons EM, Langone A, Sezer MT, Vella JP, Recupero P, Morrow JD, Ikizler TA, Himmelfarb J (2005) Transplantation 79(8): 914-9

Citation ⋅ 15849543 (PubMed)

13. Urinary tract infections after renal transplantation: a retrospective review at two US transplant centers.

Chuang P, Parikh CR, Langone A (2005) Clin Transplant 19(2): 230-5

Citation ⋅ 15740560 (PubMed)

14. Living donor kidney transplantation in a Veterans Administration medical center.

Kizilisik AT, Ray JM, Nylander WA, Langone AJ, Helderman JH, Shaffer D (2004) Am J Surg 188(5): 611-3

Citation ⋅ 15546581 (PubMed)

15. Assessing long-term nephron loss: is it time to kick the CAN grading system?

Halloran PF, Langone AJ, Helderman JH, Kaplan B (2004) Am J Transplant 4(11): 1729-30

Citation ⋅ 15476465 (PubMed)

16. Effects of diabetes and cadaveric organs on functional performance and health-related quality of life after kidney transplantation.

Kizilisik AT, Feurer ID, VanBuren DH, Wise P, Van Buren D, Hopkins J, Ray J, Nylander W, Shaffer D, Helderman JH, Langone AJ, Speroff T, Pinson CW (2003) Am J Surg 186(5): 535-9

Citation ⋅ 14599621 (PubMed)

17. Disparity between solid-organ supply and demand.

Langone AJ, Helderman JH (2003) N Engl J Med 349(7): 704-6

Citation ⋅ 12917309 (PubMed)

18. A pilot protocol of a calcineurin-inhibitor free regimen for kidney transplant recipients of marginal donor kidneys or with delayed graft function.

Shaffer D, Langone A, Nylander WA, Goral S, Kizilisik AT, Helderman JH (2003) Clin Transplant 17 Suppl 9(): 31-4

Citation ⋅ 12795665 (PubMed)

19. Identifying and addressing potentially preventable causes of renal allograft loss.

Langone AJ, Helderman JH (2002) Kidney Int 62(2): 718-9

Citation ⋅ 12110038 (PubMed)

VCKD Members

Anthony Langone, M.D.

Contact Information

Anthony James Langone M.D.

Biography

Featured Publications

1. Mammalian target of rapamycin inhibitors in organ transplantation: an unkept promise.

2. Does reduction in mycophenolic acid dose compromise efficacy regardless of tacrolimus exposure level? An analysis of prospective data from the Mycophenolic Renal Transplant (MORE) Registry.

3. Enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients experiencing gastrointestinal intolerance: a multicenter, double-blind, randomized study.

Publications

1. Mammalian target of rapamycin inhibitors in organ transplantation: an unkept promise.

2. Does reduction in mycophenolic acid dose compromise efficacy regardless of tacrolimus exposure level? An analysis of prospective data from the Mycophenolic Renal Transplant (MORE) Registry.

3. Enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients experiencing gastrointestinal intolerance: a multicenter, double-blind, randomized study.

4. Renal donation after cardiac death.

5. mTOR inhibitor-associated dermatologic and mucosal problems.

6. Recurrent pauci-immune necrotizing crescentic glomerulonephritis in a kidney transplant patient.

7. Improvement in 3-month patient-reported gastrointestinal symptoms after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients.

8. Ezetimibe reduces low-density lipoprotein cholesterol (LDL-C) in renal transplant patients resistant to HMG-CoA reductase inhibitors.

9. Ezetimibe in renal transplant patients with hyperlipidemia resistant to HMG-CoA reductase inhibitors.

10. Polyclonal antibody-induced serum sickness in renal transplant recipients: treatment with therapeutic plasma exchange.

11. The management of the failed renal allograft: an enigma with potential consequences.

12. Effect of renal transplantation on biomarkers of inflammation and oxidative stress in end-stage renal disease patients.

13. Urinary tract infections after renal transplantation: a retrospective review at two US transplant centers.

14. Living donor kidney transplantation in a Veterans Administration medical center.

15. Assessing long-term nephron loss: is it time to kick the CAN grading system?

16. Effects of diabetes and cadaveric organs on functional performance and health-related quality of life after kidney transplantation.

17. Disparity between solid-organ supply and demand.

18. A pilot protocol of a calcineurin-inhibitor free regimen for kidney transplant recipients of marginal donor kidneys or with delayed graft function.

19. Identifying and addressing potentially preventable causes of renal allograft loss.